Intellia, Cellex form CAR T cell therapy newco backed by $250M from Blackstone
Limitations to cell therapies include the types of cancers they can address and the dangerous side effects that these treatments can cause. Gene-editing biotech Intellia sees technology from clinical-stage GEMoaB as a potential solution, and it is forming a new company that will pair their respective platforms. Blackstone Life Sciences has committed $250 million to the new venture.
